ACURATE Neo™ Aortic Bioprosthesis for Implantation Using the ACURATE TA™ LP Transapical Delivery System in Patients With Severe Aortic Stenosis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 15
- 试验地点
- 4
- 主要终点
- All cause mortality
研究概览
简要总结
Trial of ACURATE neo(TM) Aortic Bioprosthesis for Implantation using the ACURATE TA(TM) LP Transapical Delivery System in Patients with Severe Aortic Stenosis for evaluating the Safety and performance of the study device
详细描述
This is a single arm, prospective, multicenter non randomised and open trial of the treatment of patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open heart surgery is considered to be high risk. All patients will be followed up to 5 years after the intervention.
The primary objective is to evaluate the safety and performance of the study device in patients presenting with severe aortic stenosis considered to be high risk for surgery Secondary objective is to evaluate adverse events and study device performance.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Device Feasibility
- 盲法
- None
入排标准
- 年龄范围
- 75 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient 75 years of age and older
- •Severe aortic stenosis defined as:
- •Mean aortic gradient > 40mmHg or o Peak jet velocity > 4.0m/sor Aortic valve area of < 1.0cm2
- •High risk candidate for conventional AVR defined as:
- •STS score ≥ 10 or Multidisciplinary heart team (cardiologist and cardiac surgeon) consensus that patient is not a surgical candidate for conventional AVR due to significant co- morbid conditions unrelated to aortic stenosis
- •NYHA Functional Class > II
- •Multidisciplinary heart team (cardiologist and cardiac surgeon) consensus that the transapical approach is the most suitable TAVI access route
- •Aortic annulus diameter from ≥ 21mm up to ≤ 27mm by CT or TEE
- •Patient willing to participate in the study and provides signed informed consent
排除标准
- •Congenital unicuspid or bicuspid aortic valve
- •Extreme eccentricity of calcification
- •Severe mitral regurgitation (> Grade 2)
- •Pre-existing prosthetic heart valve in any position and / or prosthetic ring
- •LV apex is not accessible via transapical access due to severe chest deformity
- •Previous surgery of the LV using a patch, such as the Dor procedure
- •Presence of apical LV thrombus
- •Calcified pericardium
- •Septal hypertrophy unacceptable for transapical procedure
- •Transesophageal echocardiogram (TEE) is contraindicated
- •ECHO evidence of intracardiac mass, thrombus, or vegetation
- •LVEF < 30% by ECHO
- •Emergency procedure pre-implant including CAD requiring revascularization
- •Any percutaneous intervention, except for balloon valvuloplasty (BAV) within 1 month prior to implant procedure
- •Acute myocardial infarction within 1 month prior to implant procedure
- •Previous TIA or stroke within 3 months prior to implant procedure
- •Active gastrointestinal (GI) bleeding within 3 months prior to implant procedure
- •Scheduled surgical or percutaneous procedure to be performed prior to 30 day visit
- •History of bleeding diathesis or coagulopathy or refusal of blood transfusions
- •Systolic pressure <80mmHg, cardiogenic shock, need for inotropic support or IABP
- •Primary hypertrophic obstructive cardiomyopathy (HOCM)
- •Active infection, endocarditis or pyrexia
- •Hepatic failure (> Child B)
- •Chronic renal dysfunction with serum creatinine > 2.5 mg/dL or renal dialysis
- •Refusal of surgery
- •Severe COPD requiring home oxygen
- •Neurological disease severely affecting ambulation, daily functioning, or dementia
- •Life expectancy < 12 months due to non-cardiac co-morbid conditions
- •Contraindication to study medication, contrast media, or allergy to nitinol
- •Currently participating in an investigational drug or another device study
结局指标
主要结局
All cause mortality
时间窗: 30 days
incidence of all cause mortality at 30 days
Mean aortic gradient after device implantation
时间窗: 7 days or Discharge
mean aortic gradient evaluated by echocardiography and by the site at 7days or discharge per standard post-implantation follow-up
次要结局
- rate of clinical endpoints VARC II(30 days and month 12)
- device success assessed according to composite VARC 2 criteria(7 days, 30 days, 12 months)
- procedural success(procedure)
- functional improvement from Baseline as per NYHA Functional Classification(30 days and 12 months follow up)